Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents

        The following table presents our summary balance sheet data:

    on an actual basis as of June 30, 2014;
    on a pro forma basis to give effect to the automatic preferred stock conversion, which will occur automatically upon the closing of this offering; and
    on a pro forma as adjusted basis to give further effect to our sale of              shares of common stock in this offering at an assumed initial public offering price of $        per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

        The pro forma as adjusted information presented in the summary balance sheet data is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $        per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease each of cash, total assets and total stockholders' equity on a pro forma as adjusted basis by approximately $            , assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. Similarly, each increase or decrease of 1.0 million shares offered by us at the assumed initial public offering price would increase or decrease each of cash and cash equivalents, total assets and total stockholders' equity on a pro forma as adjusted basis by approximately $            .

 
  As of June 30, 2014  
 
  Actual   Pro Forma   Pro Forma
As Adjusted
 
 
  (unaudited, in thousands)
 

Balance sheet data:

                   

Cash, cash equivalents, and marketable securities

  $ 18,141   $ 18,141   $    

Working capital

    10,031     10,031        

Total assets

    20,562     20,562        

Notes payable, including current portion

    7,505     7,505        

Convertible preferred stock

    125,870            

Accumulated deficit

    (120,896 )   (120,896 )      

Total stockholders' (deficit) equity

    (116,763 )   9,106        

 

10